Ivermectin for onchocercal eye disease (river blindness)

Hode Internal Medicine, Texas, USA. .
Cochrane database of systematic reviews (Online) (Impact Factor: 5.94). 01/2012; 8(8):CD002219. DOI: 10.1002/14651858.CD002219.pub2
Source: PubMed

ABSTRACT It is believed that ivermectin (a microfilaricide) could prevent blindness due to onchocerciasis. However, when given to everyone in communities where onchocerciasis is common, the effects of ivermectin on lesions affecting the eye are uncertain and data on whether the drug prevents visual loss are unclear.
The aim of this review was to assess the effectiveness of ivermectin in preventing visual impairment and visual field loss in onchocercal eye disease. The secondary aim was to assess the effects of ivermectin on lesions affecting the eye in onchocerciasis.
We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2012, Issue 3), MEDLINE (January 1950 to April 2012), EMBASE (January 1980 to April 2012), the metaRegister of Controlled Trials (mRCT) (, ( and the WHO International Clinical Trials Registry Platform (ICTRP) ( We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 2 April 2012.
We included randomised controlled trials with at least one year of follow-up comparing ivermectin with placebo or no treatment. Participants in the trials were people normally resident in endemic onchocercal communities with or without one or more characteristic signs of ocular onchocerciasis.
Two review authors independently extracted data and assessed trial quality. We contacted study authors for additional information. As trials varied in design and setting, we were unable to perform a meta-analysis.
The review included four trials: two small studies (n = 398) in which people with onchocercal infection were given one dose of ivermectin or placebo and followed up for one year; and two larger community-based studies (n = 4941) whereby all individuals in selected communities were treated every six or 12 months with ivermectin or placebo, whether or not they were infected, and followed for two to three years. The studies provide evidence that treating people who have onchocerciasis with ivermectin reduces the number of microfilariae in their skin and eye(s) and reduces the number of punctate opacities. There was weaker evidence that ivermectin reduced the risk of chorioretinitis. The studies were too small and of too short a duration to provide evidence for an effect on sclerosing keratitis, iridocyclitis, optic nerve disease or visual loss. One community-based study in communities mesoendemic for the savannah strain of O.volvulus provided evidence that annual mass treatment with ivermectin reduces the risk of new cases of optic nerve disease and visual field loss. The other community-based study of mass biannual treatment of ivermectin in communities affected by the forest strain of O.volvulus demonstrated reductions in microfilarial load, punctate keratitis and iridocyclitis but not sclerosing keratitis, chorioretinitis, optic atrophy or visual impairment. The study was underpowered to estimate the effect of ivermectin on visual impairment and other less frequent clinical signs. The studies included in this review reported some adverse effects, in particular an increased risk of postural hypotension in people treated with ivermectin.
The lack of evidence for prevention of visual impairment and blindness should not be interpreted to mean that ivermectin is not effective, however, clearly this is a key question that remains unanswered. The main evidence for a protective effect of mass treatment with ivermectin on visual field loss and optic nerve disease comes from communities mesoendemic for the savannah strain of O.volvulus. Whether these findings can be applied to communities with different endemicity and affected by the forest strain is unclear. Serious adverse effects were rarely reported. None of the studies, however, were conducted in areas where people are infected with Loa loa (loiasis).

  • Source
    • "(OR = 1.91, 95% CL = 1.59À2.28). Other parasites that may impact on vision include Plasmodium falciparum, Taenia solium , Echinococcus granulosus and Onchocerca volvulus (Benazzou et al., 2010; Ziaei et al., 2011; Ejere et al., 2012; Postels et al., 2013). 4.3. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Toxocariasis, caused by infection with larvae of Toxocara canis, and to a lesser extent by Toxocara cati and other ascaridoid species, manifests in humans in a range of clinical syndromes. These include visceral and ocular larva migrans (VLM and OLM, respectively), neurotoxocariasis (NT) and covert or common toxocariasis (CT). Toxocara canis is one of the most widespread public health and economically important zoonotic parasitic infections humans share with dogs, cats and wild canids, particularly foxes. This neglected disease has been shown through seroprevalence studies to be especially prevalent among children from socio-economically disadvantaged populations both in the tropics and sub-tropics and in industrialized nations. Human infection occurs by the accidental ingestion of embryonated eggs or larvae from a range of wild and domestic paratenic hosts. Most infections remain asymptomatic. Clinically overt infections may go undiagnosed, as diagnostic tests are expensive and can require serological, molecular and/or imaging tests, which may not be affordable or available. Treatment in humans varies according to symptoms and location of the larvae. Anthelmintics, including albendazole, thiabendazole and mebendazole may be given together with anti-inflammatory corticosteroids. The development of molecular tools should lead to new and improved strategies for the treatment, diagnosis and control of toxocariasis and the role of other ascaridoid species in the epidemiology of Toxocara spp. Molecular technologies may also help to reveal the public health importance of T. canis, providing new evidence to support the implementation of national control initiatives which have yet to be developed for Toxocara spp. A number of countries have implemented reproductive control programs in owned and stray dogs to reduce the number of young dogs in the population. These programs would positively impact upon T. canis transmission since the parasite is most fecund and prevalent in puppies. Other control measures for T. canis include the regular and frequent anthelmintic treatment of dogs and cats, starting at an early age, education and enforcement of laws for the disposal of canine faeces, dog legislation and personal hygiene. The existence of wild definitive and paratenic hosts complicates the control of T. canis. Increasing human and dog populations, population movements and climate change will all serve to increase the importance of this zoonosis. This review examines the transmission, diagnosis and clinical syndromes of toxocariasis, its public health importance, epidemiology, control and current research needs.
    International journal for parasitology 08/2013; 43. DOI:10.1016/j.ijpara.2013.07.004 · 3.40 Impact Factor
  • Source
    MLO: medical laboratory observer 12/2002; 34(11):10-5; quiz 16, 19.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The elimination of river blindness (onchocerciasis) in West Africa has been one of the most successful public health and economic development programs yet conducted. Control was based on aerial application of insecticides to control the aquatic, larval stages of black flies in the Simulium damnosum complex and distribution of ivermectin-based drugs to reduce incidence of the filarial worm, Onchocerca volvulus, that may ultimately result in blindness. Control efforts were long-term (1974–2003), extensive (with as many as 50,000km of river miles being treated weekly for 12years or longer), and far-reaching (distribution of drugs to almost 7 million people in 11 West African countries). The challenges and success of the program were strongly related to biodiversity: the vector S. damnosum is actually a complex of several species and subspecies, which vary in their competence in disease transmission; the filarial worm O. volvulus has different forms that vary in their virulence and incidence of producing blindness in humans; maintenance of the biodiversity of the non-target riverine fauna was a prime concern of both the control program and the donor countries that supported it; the main insecticide used to control the black fly vector was derived from a bacterium Bacillus thuringensis israelensis; and the drug used in controlling the filarial worm was derived from a soil-dwelling Streptomyces fungus. Long-term biomonitoring studies indicate that environmental damage (e.g., loss of sensitive taxa) incurred was reversed when insecticide applications ceased.
    EcoHealth 01/2004; 1(2):172-183. DOI:10.1007/s10393-004-0016-7 · 2.27 Impact Factor
Show more